GlobeNewswire
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
📈
AI Sentiment
Highly Positive
8/10
- Home
- CVKD
as of 12-05-2025 1:43pm EST
$10.02
$1.08
-9.73%
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Chart Type:
Time Range:
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 18.4M | IPO Year: | 2023 |
| Target Price: | $32.00 | AVG Volume (30 days): | 27.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.12 - $22.90 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CVKD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
buy
Model Accuracy: 69.17%
69.17%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cadrenal Therapeutics Inc. (CVKD)
Pham Quang X
Sell
CEO and Chairman
CVKD Oct 27, 2025
Avg Cost/Share
$13.99
Shares
1,315
Total Value
$18,396.85
Owned After
196,089
SEC Form 4
Szot Matthew K
Sell
Chief Financial Officer
CVKD Oct 27, 2025
Avg Cost/Share
$13.99
Shares
1,800
Total Value
$25,182.00
Owned After
9,933
SEC Form 4
Pham Quang X
Sell
CEO and Chairman
CVKD Oct 24, 2025
Avg Cost/Share
$14.03
Shares
1,129
Total Value
$15,839.87
Owned After
196,089
SEC Form 4
Szot Matthew K
Sell
Chief Financial Officer
CVKD Oct 24, 2025
Avg Cost/Share
$13.99
Shares
1,800
Total Value
$25,182.00
Owned After
9,933
SEC Form 4
Pham Quang X
Sell
CEO and Chairman
CVKD Oct 13, 2025
Avg Cost/Share
$14.15
Shares
1,800
Total Value
$25,470.00
Owned After
196,089
SEC Form 4
Szot Matthew K
Sell
Chief Financial Officer
CVKD Oct 13, 2025
Avg Cost/Share
$14.07
Shares
1,800
Total Value
$25,326.00
Owned After
9,933
SEC Form 4
Pham Quang X
Sell
CEO and Chairman
CVKD Oct 9, 2025
Avg Cost/Share
$14.02
Shares
1,800
Total Value
$25,236.00
Owned After
196,089
SEC Form 4
Szot Matthew K
Sell
Chief Financial Officer
CVKD Oct 9, 2025
Avg Cost/Share
$13.99
Shares
1,693
Total Value
$23,685.07
Owned After
9,933
SEC Form 4
Szot Matthew K
Sell
Chief Financial Officer
CVKD Oct 6, 2025
Avg Cost/Share
$13.99
Shares
107
Total Value
$1,496.93
Owned After
9,933
SEC Form 4
Pham Quang X
Sell
CEO and Chairman
CVKD Oct 1, 2025
Avg Cost/Share
$14.01
Shares
881
Total Value
$12,342.81
Owned After
196,089
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pham Quang X | CVKD | CEO and Chairman | Oct 27, 2025 | Sell | $13.99 | 1,315 | $18,396.85 | 196,089 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 27, 2025 | Sell | $13.99 | 1,800 | $25,182.00 | 9,933 | |
| Pham Quang X | CVKD | CEO and Chairman | Oct 24, 2025 | Sell | $14.03 | 1,129 | $15,839.87 | 196,089 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 24, 2025 | Sell | $13.99 | 1,800 | $25,182.00 | 9,933 | |
| Pham Quang X | CVKD | CEO and Chairman | Oct 13, 2025 | Sell | $14.15 | 1,800 | $25,470.00 | 196,089 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 13, 2025 | Sell | $14.07 | 1,800 | $25,326.00 | 9,933 | |
| Pham Quang X | CVKD | CEO and Chairman | Oct 9, 2025 | Sell | $14.02 | 1,800 | $25,236.00 | 196,089 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 9, 2025 | Sell | $13.99 | 1,693 | $23,685.07 | 9,933 | |
| Szot Matthew K | CVKD | Chief Financial Officer | Oct 6, 2025 | Sell | $13.99 | 107 | $1,496.93 | 9,933 | |
| Pham Quang X | CVKD | CEO and Chairman | Oct 1, 2025 | Sell | $14.01 | 881 | $12,342.81 | 196,089 |
Latest Cadrenal Therapeutics Inc. News
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
Compare CVKD vs Leading Stocks
See how CVKD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.